Article Text

Download PDFPDF

441 Development of a repeated challenge potency assay for evaluation of immune cell-mediated cytotoxicity in vitro
  1. Denise Sullivan1,
  2. Sayem H Bhuiyan1,
  3. George Huang2,
  4. Danielle Califano1,
  5. Stacie Chvatal1 and
  6. Daniel Millard1
  1. 1Axion Biosystems, Atlanta, GA, USA
  2. 2Apexigen, San Carlos, CA, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background The development of immunotherapies relies on the use of in vitro potency assays—which are key for understanding complex interactions between immune (effector) cells and cancer (target) cells. Although a variety of in vitro assays are used to characterize the cell-mediated cytotoxicity of engineered immune cells, they often are unable to differentiate between various CAR T products that may be susceptible to exhaustion or reduced potency that can impede complete tumor eradication. Thus, in vitro potency assays that can recapitulate conditions of high tumor burden, induce T cell exhaustion, and allow for changes in T cell killing kinetics to be monitored in real-time are critical. Here, we describe an in vitro potency assay that quantifies immune cell-mediated cytotoxicity in response to repeated challenges with target cells.

Methods The repeated challenge assay was performed with two separate protocols, each providing a unique assessment of the effector cell function. In the first method, SKOV3 target cells were seeded into a 96-well microplate with embedded electrodes in the substrate that detect the attachment and proliferation of target cells. HER-2 CAR T cells were added at 24 hours post SKOV3 cell seeding at E:T = 1:1. Cytolysis of the target cells was calculated by comparing treated wells to no treatment control wells. Every 24 hours, additional SKOV3 target cells were added to repeatedly challenge CAR T potency, with total tumor cell killing computed from the area under the impedance curve.

Results The repeated challenge condition reached complete killing after the 6th tumor cell challenge (144 hours), whereas the single challenge condition reached complete killing within 96 hours of effector cell addition. Flow cytometry revealed that the effector cells proliferated significantly more for the repeated challenge condition (4.7x increase) than the single challenge condition (1.5x increase). In the second method, the CAR T cells were removed after each challenge, counted, and added to a new plate SKOV3 cells at E:T=1:1. Here, the E:T ratio was kept constant for each challenge, allowing a direct comparison of the time to kill 50% of the SKOV3 population for each subsequent challenge. The KT50 decreased from the first challenge (19.9 hours) to the fourth challenge (83.5 hours). Flow cytometry revealed a reduction in CD8+ cells for the repeated challenge condition, indicating a change in the make-up of the effector cell population.

Conclusions The paradigms described above facilitate a label-free, in vitro workflow to assess potency of immune effector cells across repeated challenges.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.